Investegate |Junshi Biosciences Announcements | Junshi Biosciences: CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC
December 13, 2020 19:00 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA
SHANGHAI, China, Dec. 14, 2020 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the Independent Data Monitoring Committee (IDMC) has determined that Toripalimab (product code: JS001) in combination with standard chemotherapy as the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) has reached its pre-specified primary endpoint of Progression Free Survival (PFS) at the interim analysis of a randomized, double-blind, multi-center, phase III clinical study “CHOICE-01
(2)
SHANGHAI, China, Dec. 14, 2020 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the Independent Data Monitoring Committee (IDMC) has determined that Toripalimab (product code: JS001) in combination with standard chemotherapy as the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) has reached its pre-specified primary endpoint of Progression Free Survival (PFS) at the interim analysis of a randomized, double-blind, multi-center, phase III clinical study CHOICE-01 (Clinicaltrial.gov identifier: NCT03856411). The Company will initiate the process to submit a supplemental New Drug Application (NDA) to the National Medical Products Administration (NMPA) in the near future.